Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology | Obstetrics/Gynecology (Women’s Health) | Family Medicine

Endometrial Cancer Clinical Trials


A listing of Endometrial Cancer medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.

Alabama

Mobile : University of South Alabama / Mitchell Cancer Institute Univ South Alabama

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Arizona

Pheonix : St. Joseph's Hospital and Medical Center

Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer

California

Concord : John Muir Clinical Research Center

Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer

Fullerton : St. Jude Heritage Medical Group St Jude

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Los Angeles : Cedars Sinai Medical Center TKI258A2211 (SC)

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Los Angeles : UCLA/ University of California Los Angeles UCLA 3

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Los Angeles : USC/Kenneth Norris Comprehensive Cancer Center USC 2

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

View More »

Santa Maria : Central Coast Medical Oncology Corporation

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Colorado

Greenwood Village : Rocky Mountain Cancer Centers Dept. of Rocky Mountain Cancer

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Connecticut

Farmington : University of Connecticut Health Center

Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer

New Haven : Smilow Cancer Hospital at Yale New Haven

Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer

New Haven : Yale University School of Medicine

Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers

Florida

Orlando : Florida Hospital Cancer Institute FL Hosp

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Tampa : H. Lee Moffitt Cancer Center and Research Institute

Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids

Georgia

Savannah : Memorial University Medical Center

GOG-0229K: A Phase II Evaluation of BIBF 1120 (IND #) in the Treatment of Recurrent or Persistent Endometrial Carcinoma

Savannah : Memorial University Medical Center

GOG-0229L: A Phase II Trial of AMG 386 (IND# ), a Selective Angiopoietin ½ Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium

Indiana

Indianapolis : Indiana University Health Goshen Center for Cancer IU Simon Cancer

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Maryland

Baltimore : Greater Baltimore Medical Center

Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer

Michigan

Detroit :

Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors

Detroit : Investigational Site Number 1326

Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Cancer

Nebraska

Lincoln : Southeast Nebraska Oncology Cancer Center

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

New York

Bronx : Montefiore Medical Center

Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer

New York :

Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors

North Carolina

Asheville : Hope A Woman's Cancer Center

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Chapel Hill : University of North Carolina

Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer

Durham : Duke University Medical Center Duke3

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Durham : Duke University School of Medicine

Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer

Ohio

Hilliard : The Ohio State University

Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer

Rhode Island

Providence : Investigational Site Number 1142

Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Cancer

South Carolina

Greenville : Cancer Centers of the Carolinas SC-1

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Tennessee

Chattanooga : Community Oncology Research Network

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Memphis : The West Clinic SC

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Nashville : Vanderbilt University Medical Center SC-2

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Nashville :

Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors

Texas

Bedford : Texas Oncology, P.A. Tex Onc (3)

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Bedford : Texas Oncology, P.A. Austin

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Fort Worth : Texas Oncology, P.A. SC

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Houston : UT MD Anderson Cancer Center

Chemoradiation-Induced Nausea and Emesis: Quality of Life

San Antonio : South Texas Oncology and Hematology, PA South Tex Onc

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Virginia

*see Various Departments* : Virginia Oncology Associates VOA - Lake Wright

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Washington

Spokane : Cancer Care Northwest SC

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Belgium

Wilrijk : Investigational Site Number 3218

Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Cancer

Brazil

Belo Horizonte : Novartis Investigative Site

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Porto Alegre : Novartis Investigative Site

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Ribeirao Preto : Novartis Investigative Site

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Italy

Candiolo : Novartis Investigative Site

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Milano : Novartis Investigative Site

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Pisa : Novartis Investigative Site

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Korea, Republic of

Seoul : Asan Medical Center

Efficacy Study of Chemotherapy Followed by Radiation Therapy to Treat Endometrial Cancer

Seoul : Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center

Efficacy Study of FloSeal for Prevention of Lymphocele After Lymphadenectomy for Gynecologic Cancer

New Zealand

Grafton, Auckland : Novartis Investigative Site

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Spain

Barcelona : Novartis Investigative Site

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Córdoba : Novartis Investigative Site

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Majadanonda : Novartis Investigative Site

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Málaga : Novartis Investigative Site

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Sabadell : Novartis Investigative Site

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

United Kingdom

Nottingham : Novartis Investigative Site

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer